RXRX Q4 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-2.0% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$65M-2598.4% margin

Net Income

-$65M-2597.3% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$66M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$610M

Total Liabilities

$67M

Stockholders' Equity

$543M

Cash & Equivalents

$285M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-2.0%
Gross Profit	$3M	$3M	-2.0%
Operating Income	-$65M	-$26M	-153.9%
Net Income	-$65M	-$26M	-152.0%

Revenue Segments

License and Service

$3M99%

Grant

$33,0001%